Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM

Trial Profile

A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DA 1241 (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Dong-A ST
  • Most Recent Events

    • 29 Jun 2021 Results (n=24) assessing safety, tolerability, and pharmacokinetics from part 1 of a phase 1b multiple ascending dose study in healthy volunteers, presented at the 81st Annual Scientific Sessions of the American Diabetes Association
    • 29 Jun 2021 Results (n=72) of Part 2 assessing the safety, tolerability and PK profiles of DA-1241, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
    • 08 Feb 2021 According to a Dong-A ST Media Release, data from this trial will be presented at the American Diabetes Association conference 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top